Out of all the phenomena associated with menopause, bone loss is one with the most serious consequences, leading to osteopenia and osteoporotic fractures.

Studies of the relationships between BMD and fractures conclude that preservation of bone mass is critical for avoidance of osteoporotic fractures.

Early prevention is widely advocated as the optimal medical solution for osteoporotic fractures. Prevention should be initiated at the age at which a woman reaches menopause. However, the lack of consensus on what treatment to provide reflects the trade offs between the known and potential benefits vs. risks of the available treatments for the long-term use, which is critical in order to provide constant support to the bone.

A new approach to treatment, in which bone can be protected without incurring risks associated with long-term use or adverse effects that induce patients to discontinue therapy, is essential for maintaining the health, quality of life, and independence of women throughout their life.

The following studies will show that Femarelle^® provides a safe and effective therapy for the management of bone loss, thus providing women with a sound therapeutic option that they can rely on for better health and higher quality of life both for the short and long run.